The combination of PD-1 blockade and CCR2 inhibition (both genetic and pharmacological with the CCR2 agonist CCX872) improved survival of KR158 glioma-bearing mice, and reduced accumulation of CD11b+/Ly6Chi/PD-L1+ MDSCs in gliomas. The gene discussed is CCR2; the disease is central nervous system cancer.